Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.62 |
| ▸ | SCD | O00767 | 3/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18610914 | 1.00 | SLC6A4 (0.62) | SLC6A4SLC6A2SLC6A3SCDHTR1A | |
| SCHEMBL20329796 | 0.81 | SLC6A4 (0.62) | SLC6A4SLC6A2SLC6A3SCDHTR1A | |
| SCHEMBL19527586 | 0.81 | SLC6A4 (0.62) | SLC6A4SLC6A2SLC6A3SCDHTR1A | |
| SCHEMBL22355169 | 0.80 | SLC6A4 (0.57) | SLC6A4SLC6A2SLC6A3SCDGRIN1 | |
| SCHEMBL20351812 | 0.80 | SLC6A4 (0.57) | SLC6A4SLC6A2SLC6A3SCDGRIN1 | |
| SCHEMBL20329798 | 0.80 | SLC6A4 (0.57) | SLC6A4SLC6A2SLC6A3SCDEPHX2 | |
| SCHEMBL9281104 | 0.79 | SLC6A4 (0.65) | SLC6A4SLC6A2SLC6A3SCDEPHX2 | |
| SCHEMBL23842635 | 0.78 | SLC6A4 (0.60) | SLC6A4SLC6A2SLC6A3HTR1A | |
| Hydrochloric Acid SCHEMBL69882 | 0.77 | SLC6A4 (0.59) | SLC6A4SLC6A2SLC6A3HTR1A | |
| SCHEMBL18610899 | 0.77 | SLC6A2 (0.53) | SLC6A4SLC6A2SLC6A3HTR1AGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170066783-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066783-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders | CFD, F12, F3 | SLC6A4 3842/4885SLC6A2 2764/4885SLC6A3 3030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.